Epidemiological Analysis and Patient Profile of Lung Cancer in the Brazilian Public Health System: A Real-World Data Study
Author(s)
Ana Almeida, MSc1, Thais Berra, PhD1, Angelica Santos, PhD1, Renato Vitorasso, PhD1, Caio Martins, BSc2, Leticia Jabase, PgD2, Bengt Liljas, PhD3.
1Real World Evidence, IQVIA, São Paulo, Brazil, 2AstraZeneca, Cotia, Brazil, 3AstraZeneca, Gaithersburg, MD, USA.
1Real World Evidence, IQVIA, São Paulo, Brazil, 2AstraZeneca, Cotia, Brazil, 3AstraZeneca, Gaithersburg, MD, USA.
OBJECTIVES: Lung Cancer (LC) is the leading cause of cancer mortality and the fourth most incident type of cancer in Brazil. Prognosis varies according to disease stage, genetic mutations, histological type, and treatment. This study aims to describe the epidemiological profile of patients with LC in the Brazilian public healthcare system, by stage.
METHODS: This retrospective study included patients aged 18 years or older, identified with International Classification of Diseases Tenth Revision (ICD-10) code C34, from January 2015 to December 2023. Data were retrieved from the Brazilian Informatics Department of the National Health System (DATASUS) and linked with the Ambulatory Information System (SIA) and Hospital Information System (SIH) databases through patient identifiers (e.g., date of birth, gender, and zip code).
RESULTS: 86,491 individuals with ICD-10 code C34 were identified from 2015 to 2023, averaging 9,610 new LC patients per year. Majority of patients had their diagnosis at advanced cancer stages: 55.45% at stage IV, 22.32% at stage III, 5.25% at stage II and 6.90% at stage I. The average age of patients with LC was 64 years, most of them were male (54.63%), white (56.62%), and from the Southeast (42.20%) and South (27.77%) regions, particularly from the states of São Paulo (22,72%), Rio Grande do Sul (13,23%) and Minas Gerais (10,81%). Majority of patients were treated with chemotherapy (58,1%), radiotherapy (29,4%) and surgery (12,4%). On average, patients received 6.52 chemotherapy sessions and only one radiotherapy session or surgery treatment. Only 4.72% of patients underwent treatment with targeted therapy and 0.10% received immunotherapy. These treatments were administered alone or combined between them.
CONCLUSIONS: Understanding the current scenario of LC patients is important for developing and amplifying strategies, such as screening programs, early diagnosis, molecular testing and access to innovative treatments, and therefore, enhancing patient prognosis in the Brazilian public health system.
METHODS: This retrospective study included patients aged 18 years or older, identified with International Classification of Diseases Tenth Revision (ICD-10) code C34, from January 2015 to December 2023. Data were retrieved from the Brazilian Informatics Department of the National Health System (DATASUS) and linked with the Ambulatory Information System (SIA) and Hospital Information System (SIH) databases through patient identifiers (e.g., date of birth, gender, and zip code).
RESULTS: 86,491 individuals with ICD-10 code C34 were identified from 2015 to 2023, averaging 9,610 new LC patients per year. Majority of patients had their diagnosis at advanced cancer stages: 55.45% at stage IV, 22.32% at stage III, 5.25% at stage II and 6.90% at stage I. The average age of patients with LC was 64 years, most of them were male (54.63%), white (56.62%), and from the Southeast (42.20%) and South (27.77%) regions, particularly from the states of São Paulo (22,72%), Rio Grande do Sul (13,23%) and Minas Gerais (10,81%). Majority of patients were treated with chemotherapy (58,1%), radiotherapy (29,4%) and surgery (12,4%). On average, patients received 6.52 chemotherapy sessions and only one radiotherapy session or surgery treatment. Only 4.72% of patients underwent treatment with targeted therapy and 0.10% received immunotherapy. These treatments were administered alone or combined between them.
CONCLUSIONS: Understanding the current scenario of LC patients is important for developing and amplifying strategies, such as screening programs, early diagnosis, molecular testing and access to innovative treatments, and therefore, enhancing patient prognosis in the Brazilian public health system.
Conference/Value in Health Info
2025-05, ISPOR 2025, Montréal, Quebec, CA
Value in Health, Volume 28, Issue S1
Code
EE274
Topic
Economic Evaluation
Topic Subcategory
Cost/Cost of Illness/Resource Use Studies
Disease
SDC: Oncology